TLC 065
Alternative Names: TLC-065Latest Information Update: 27 Dec 2023
At a glance
- Originator Mitobridge
- Developer OrsoBio
- Class Hepatoprotectants
- Mechanism of Action Aminocarboxymuconate semialdehyde decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fatty liver; Mitochondrial disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 10 Nov 2023 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) before November 2023
- 10 Nov 2023 Pharmacodynamics and adverse events data from a preclinical trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 02 Nov 2022 OrsoBio acquires ACMSD inhibitor program from Mitobridge